Publications for Andrew Biggin

2018

Biggin, A. (2018). A 21st century plague of biblical proportions. *Journal of Paediatrics and Child Health*, 54(12), 1292-1293. [More Information]

Simm, P., Biggin, A., Zacharin, M., Rodda, C., Tham, E., Siafarikas, A., Jefferies, C., Hofman, P., Jensen, D., Woodhead, H., Munns, C., et al (2018). Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. *Journal of Paediatrics and Child Health*, 54(3), 223-233. [More Information]

Fiscaletti, M., Coorey, C., Biggin, A., Briody, J., Little, D., Schindeler, A., Munns, C. (2018). Diagnosis of Recurrent Fracture in a Pediatric Cohort. *Calcified Tissue International*, 103(5), 529-539. [More Information]

Biggin, A., Enriquez, A., Wong, M., Bennetts, B., Lau, C., Chan, C., Pinner, J., Adelstein, S., Ades, L. (2018). Hemophagocytic Lymphohistiocytosis in Loeys-Dietz Syndrome. *Journal of Clinical Immunology*, 38(3), 234-236. [More Information]

Fiscaletti, M., Biggin, A., Bennetts, B., Wong, K., Briody, J., Pacey, V., Birman, C., Munns, C. (2018). Novel variant in Sp7/Osx associated with recessive osteogenesis imperfecta with bone fragility and hearing impairment. *Bone*, 110, 66-75. [More Information]

2017

Biggin, A., Munns, C. (2017). Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta. *Current Osteoporosis Reports*, 15(5), 412-418. [More Information]

2015

Korula, S., Titmuss, A., Biggin, A., Munns, C. (2015). A Practical Approach to Children with Recurrent Fractures. *Endocrine Development*, 28, 210-225. [More Information]

Munns, C., Fahiminiya, S., Poudel, N., Munteanu, M., Majewski, J., Sillence, D., Metcalf, J., Biggin, A., Glorieux, F., Fassier, F., et al (2015). Homozygosity for Frameshift Mutations in XYLT2 Result in a Spondylo-Ocular Syndrome with Bone Fragility, Cataracts, and Hearing Defects. *American Journal of Human Genetics*, 96(6), 971-978. [More Information]

Biggin, A., Zheng, L., Briody, J., Coorey, C., Munns, C. (2015). The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta. *Hormone Research in Paediatrics*, 83(3), 183-189. [More Information]

2014

Biggin, A., Munns, C. (2014). Bisphosphonates in Osteogenesis Imperfecta. In Gordon L. Klein (Eds.), *Bone Drugs in Pediatrics: Efficacy and Challenges*, (pp. 67-80). New York: Springer. [More Information]

Biggin, A., Briody, J., Ormshaw, E., Wong, K., Bennetts, B., Munns, C. (2014). Fracture during Intravenous Bisphosphonate Treatment in a Child with Osteogenesis Imperfecta: An Argument for a More Frequent, Low-Dose Treatment Regimen. *Hormone Research in Paediatrics*, 81(3), 204-210. [More Information]

Dasgupta, D., Wee, M., Reyes, M., Li, Y., Simm, P., Sharma, A., Schlingmann, K., Janner, M., Biggin, A., Lazier, J., Munns, C., et al (2014). Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and Nephrocalcinosis. *Journal of the American Society of Nephrology*, 25(10), 2366-2375. [More Information]

Biggin, A., Munns, C. (2014). Osteogenesis Imperfecta: Diagnosis and Treatment. *Current Osteoporosis Reports*, 12(3), 279-288. [More Information]

2013

Biggin, A., Briody, J., Ramjan, K., Middleton, A., Waugh, M., Munns, C. (2013). Evaluation of bone mineral density and morphology using pQCT in children after spinal cord injury. *Developmental Neurorehabilitation*, 16(6), 391-397. [More Information]

Ooi, H., Briody, J., Biggin, A., Cowell, C., Munns, C. (2013). Intravenous Zoledronic Acid Given Every 6 Months in Childhood Osteoporosis. *Hormone Research in Paediatrics*, 80(3), 179-184. [More Information]

2006

Ades, L., Sullivan, K., Biggin, A., Haan, E., Brett, M., Holman, K., Dixon, J., Robertson, S., Holmes, A., Rogers, J., Bennetts, B. (2006). FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited. *American Journal of Medical Genetics, Part A*, 140(10), 1047-1058. [More Information]

2005

Biggin, A., Henke, R., Bennetts, B., Thorburn, D., Christodoulou, J. (2005). Mutation screening of the mitochondrial genome using denaturing high-performance liquid chromatography. *Molecular Genetics and Metabolism*, 84(1), 61-74. [More Information]